Related references
Note: Only part of the references are listed.Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Benjamin L. Lampson et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab
Preetesh Jain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
D. Jones et al.
LEUKEMIA (2017)
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Dan A. Landau et al.
NATURE COMMUNICATIONS (2017)
Treatment of Richter's Syndrome
Adalgisa Condoluci et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
Preetesh Jain et al.
CANCER (2017)
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
Sabah Kadri et al.
BLOOD ADVANCES (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Rose Lou Marie C. Agbay et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory
Rashmi Kanagal-Shamanna et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger et al.
NATURE COMMUNICATIONS (2016)
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
Shruti Sharma et al.
ONCOTARGET (2016)
Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
Rashmi Kanagal-Shamanna et al.
ONCOTARGET (2016)
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu et al.
BLOOD (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
Shuang Q. Zhang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
S. Cheng et al.
LEUKEMIA (2015)
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach et al.
BLOOD (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova et al.
BLOOD (2013)
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Giulia Fabbri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia
Rachel Sargent et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Share Paper
